Ozempic and GLP-1 Agonists as Lifestyle Drugs

Ozempic and GLP-1 agonists spark outrage as Hollywood's weight-loss secret, with ethical debates over drug shortages for diabetic patients. Data shows semaglutide users lose an average of 15% body weight over 68 weeks, per the New England Journal of Medicine (2021). However, reports of 40% muscle loss and severe rebound gain make this trend 30% more polarizing than #2’s average for lifestyle drugs. Cheaper than the typical clinic-supervised plan, but with catastrophic metabolic risks for non-diabetics.